Overview

* OrthoPediatrics ( KIDS ) Q3 revenue grows 12% yr/yr to $61.2 mln, driven by Trauma & Deformity

* Adjusted EBITDA for Q3 rises 56% yr/yr but misses analyst expectations

* Company reports GAAP diluted loss per share of $0.50, non-GAAP loss of $0.24

Outlook

* Company forecasts full-year 2025 revenue between $233.5 mln and $234.5 mln

* Company aims for free cash flow break-even in 2026

Result Drivers

* TRAUMA & DEFORMITY GROWTH - Co attributes 17% revenue growth in Trauma & Deformity to strong performance of PNP Femur, PNP Tibia, DF2, and OPSB products

* SCOLIOSIS SALES - Scoliosis revenue increased 4%, driven by Response and ApiFix non-fusion system sales, offset by decline in 7D unit sales

* DOMESTIC REVENUE INCREASE - Domestic revenue rose 14%, driven by strong sales in core product lines, despite challenges in 7D sales

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.50

Q3 Net -$11.80

Income mln

Q3 Miss $6.20 $6.49

Adjusted mln mln (6

EBITDA Analysts

)

Q3 Gross 74%

Margin

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for OrthoPediatrics Corp ( KIDS ) is $23.00, about 26.3% above its October 27 closing price of $16.96

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)